Search AMPH
Amphastar Pharmaceuticals, Inc.
NasdaqGS · CIK 1297184
Last close25.43
Daily change+0.08 (0.32%)
10 Years gain+31.49%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
AMPH · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
59.8Momentum
0.0Acceleration
11.9Confidence
91.0Annual Revenue14
Quarterly Revenue54
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.8 / 25
Quality14.0 / 25
Capital Efficiency10.1 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 11.355%.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 3.6483 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 10.8388 percentage points.
ROIC declining · MEDIUMROIC declined by 4.0321 percentage points.
Key Metrics
Revenue Growth TTM0.75%OK
Revenue CAGR 3Y12.99%OK
Gross Margin48.37%OK
Operating Margin16.76%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC16%OK
Incremental Operating Margin 3Y14.83%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-11.36%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $719.89M | $356.06M | $140.40M | $156.12M | $121.23M | 49.46% | 19.5% | 16.84% | 9.9% | 48.22M |
| 2025 FY Dec 31, 2024 | $731.97M | $373.86M | $205.42M | $213.39M | $172.35M | 51.08% | 28.06% | 23.55% | 16.43% | 52.06M |
| 2025 FY Dec 31, 2023 | $644.40M | $351.12M | $196.99M | $183.50M | $145.34M | 54.49% | 30.57% | 22.55% | 22.67% | 53M |
| 2024 FY Dec 31, 2022 | $498.99M | $248.86M | $107.50M | $89.18M | $65.15M | 49.87% | 21.54% | 13.06% | 21% | 52.43M |
| 2023 FY Dec 31, 2021 | $437.77M | $199.74M | $69.89M | $97.99M | $70.54M | 45.63% | 15.96% | 16.11% | 14.46% | 49.78M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $721.33M | sum latest 4 fiscal quarters Revenue | OK | 0001297184-26-000047, 0001297184-25-000064 |
| Revenue Growth TTM | 0.75% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001297184-26-000047, 0001297184-25-000064 |
| Revenue CAGR 3Y | 12.99% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001297184-26-000009 |
| Revenue CAGR 5Y | 15.53% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001297184-26-000009 |
| Gross Profit CAGR 3Y | 12.68% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001297184-26-000009 |
| Operating Income Growth | -38.82% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001297184-26-000047, 0001297184-25-000064 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 48.37% | Gross Profit / Revenue | OK | 0001297184-26-000047, 0001297184-25-000064 |
| Operating Margin | 16.76% | Operating Income / Revenue | OK | 0001297184-26-000047, 0001297184-25-000064 |
| ROIC | 16% | NOPAT / Average Invested Capital | OK | 0001297184-26-000047, 0001297184-25-000064 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001297184-26-000047 |
| Current Ratio | 2.4x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $16.31 | Revenue / Diluted Shares | OK | 0001297184-26-000047, 0001297184-25-000064 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |